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a b s t r a c t
Neurosteroids are involved in Central Nervous System development, brain functionality and neu-
roprotection but little is known about regulators of their biosynthesis. Recently gonadotropins,
Gonadotropin-releasing Hormone (GnRH) and their receptors have been localized in different brain
regions, such as hippocampus and cortex.
Using human neuronal-like cells we found that GnRH up-regulates the expression of key genes of
cholesterol and steroid synthesis when used in a narrow range around 1.0nM. The expression of Hydrox-
ysterol D24-reductase (seladin-1/DHCR24), that catalyzes the last step of cholesterol biosynthesis, is
increased by 50% after 90min of incubation with GnRH. StAR protein and P450 side chain cleavage
(P450scc) are up-regulated by 3.3 times after 90min and by 3.5 times after 3h, respectively. GnRH action
is mediated by LH and 1.0nM GnRH enhances the expression of LH as well.
A two fold increase of cell cholesterol is induced after 90minofGnRH incubation and17-estradiol (E2)
production is increased after 24, 48 and 72h. These data indicate for the first time that GnRH regulates
both cholesterol and steroid biosynthesis in human neuronal-like cells and suggest a new physiological
role for GnRH in the brain.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Steroid hormones have been traditionally considered as exclu-
sively originating from adrenals and gonads with their synthesis
regulated by the hypothalamic-pituitary-adrenal (HPA) and the
hypothalamic-pituitary-gonadal (HPG) axes, respectively. Steroids
are small cholesterol-derived, lipophilic molecules that can cross
the plasmamembrane and the blood–brain barrier; thus the spatial
specificity of their action has been attributed to steroid recep-
tors expression by target cells. However, from the past twenty
years new evidences are contributing to a redefinition of these
concepts: local de novo steroidogenesis has been demonstrated
in many peripheral tissues [1–5]. Moreover, for cholesterol, the
starting molecule of steroids biosynthesis, the de novo synthesis
has now been completely elucidated [6] and recent data demon-
strate that gonadotropins (in particular LH) are able to regulate
this biosynthetic pathway, suggesting a strong associationbetween
cholesterol and steroid biosynthesis [7]. One of the most important
local site where peripheral steroidogenesis has been demonstrated
Abbreviation: E2, 17-estradiol.
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is the Central Nervous System (CNS). The concept of endogenous
steroid synthesis in the brain, or neurosteroidogenesis, arises from
the observations, made in the 1980s by Baulieu and colleagues
[4,8,9], of the presence of steroids such as dehydroepiandrosterone,
pregnenolone and their sulphates in rat brain. Their concentration
was greater than those found in the circulation and remained high
after adrenalectomy and gonadectomy. Starting from these data,
neuroactive steroids have received great attention as autocrine
and paracrine regulators of brain function. Neurosteroids are a
class of neuroactive compounds involved in CNS development,
in adult brain functionality and in neuroprotection [10–13]. The
absence or reduced concentrations of neurosteroids during devel-
opment and in adultsmay be associatedwith neurodevelopmental,
psychiatric, or behavioural disorders and neurodegeneration [13].
Despite the continuous identification of new and unexpected
functions of these compounds, little is known about the regu-
lators of their biosynthetic pathway in the brain and existing
data are mainly focused on neurotransmitters and neuropeptides
[14].
Recent studies indicate that FSH, LH, ACTH and their recep-
tors are locally expressed in tissues that are target of peripheral
hormones (i.e. CNS and the immune system), suggesting the pres-
ence of miniature HPG and HPA axis homologs that are able to
autonomously regulate local steroidogenesis [15]. GnRH receptors
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(GnRHRs) have been localized in many regions of the brain such
as the hippocampus and cortex and detected in human neuronal
cell models like the neuroblastoma SH-SY5Y and M17 cells [16,17].
In M17 cells GnRH induces an up-regulation of the LH subunit
[17] and LH mediates neuronal pregnenolone production increas-
ing Steroidogenic Acute Regulatory protein (StAR) expression [18].
Moreover, GnRH regulates estrogen synthesis and spine synapse
density in rat primary hippocampal cultures [19].
On the other hand, cholesterol that serves as a precursor
for neurosteroids, derives totally from de novo synthesis in this
compartment [20,21]. The enzyme that catalyzes the last step
of cholesterol biosynthesis is 3-hydroxysterol 24-reductase
(DHCR24) that is also named seladin-1 (for SELective Alzheimer
Disease INdicator-1) because its expression is markedly reduced in
brain areas affected by Alzheimer’s disease [22]. We have recently
demonstrated that the expression of seladin-1/DHCR24 is up-
regulated by estrogen in a human long term primary culture of
GnRH secreting foetal neuroblasts (FNC) [23,24]. Nothing is known
about the influence of GnRH on cholesterol biosynthesis although
the possibility of shared regulators for cholesterologenesis and
steroidogenesis has been hypothesised [7].
A better understanding of how the biosynthetic pathways lead-
ing to cholesterol and steroids are controlled in CNS and the
possible identification of common regulators could improve our
knowledge of the physiology of the human brain and open new
perspectives in the pharmacological treatment of its disturbances.
For this purpose we examined whether GnRH is able to stim-
ulate cholesterol synthesis and steroidogenesis in two human
neuronal cell models: SH-SY5Y, a neuroblastoma cell line used as a
human neuronal model and possessing the GnRH receptor (GnRH-
R) [25,26], and FNC, a model of human neuroblast [27]. FNCs are
a long term primary culture of neuroblast deriving from foetal
olfactoryepitheliumandretainsbotholfactoryandneuroendocrine
characteristics, producing GnRH and expressing its receptor.
2. Materials and methods
2.1. Materials
All reagents were of analytical grade or the highest purity avail-
able. Cholesterol, GnRH (type I), LH, Bradford reagent, BSTFA and
other chemicals were from Sigma (Milan, Italy), unless otherwise
stated. Stigmasterol was from Steraloids Inc. (Newport, RI, USA).
2.2. Cell cultures and hormone treatments
Human SH-SY5Y neuroblastoma cells were obtained from
A.T.C.C. (Manassas, VA, USA) and were cultured in DMEM supple-
mented with 10% FBS, 1.0% glutamine and 1.0% antibiotics from
Sigma. FNC were isolated from human foetal olfactory neuroep-
ithelium, cloned, and long-term cell cultures were established and
propagated in Coon’s modified Ham’s F12 from Life Technologies
(Grand Island, NY, USA), supplemented with 10% FBS and 1.0%
antibiotics, as described previously [27]. The cells were maintained
in a 5.0% CO2 humidified atmosphere at 37 ◦C in tissue plasticware
from PBI International (Milan, Italy).
Stock solution of GnRH was prepared at 10mg/ml concentra-
tion in ultrapure water and stored at −20 ◦C in working aliquots.
Stock solution of LH was prepared at 50 IU/ml in water and stored
at 4 ◦C. Cells were plated 48h prior to treatment at a density
of approximately 2.0×105 cells/well in six-wells plates and of
1.0×106 cells/plate in 10-cm dishes. The following day, cultures
were placed in serum-free medium for 24h prior to treatment
with 0.01–1000nMGnRHor 100mIU/ml LH at 37 ◦C for the incuba-
tion times indicated in Section 3. Medium was changed with fresh
medium containing the appropriate hormone concentration every
24h.
LH-receptor was blocked using the LHR(H-50) antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), raised against an
extracellular domain of human LH-receptor. SH-SY5Y cells were
incubated for 1h at 37 ◦C with the LHR(H-50) antibody diluted
1:200 in serum-free medium before the hormone treatment.
2.3. Isolation of RNA, synthesis of cDNA and RT-PCR assay
Cells were plated at a density of 1.0×106 cells in 10-cm dishes,
maintained in serum free medium for 24h and than treated with
various concentrations of GnRH for the indicated periods.
Total RNA was isolated from SH-SY5Y and FNC cells using
the RNEasy Mini Kit (Qiagen, Hilden, Germany) and treated with
RNase-free DNase I (Qiagen) during RNA purification following the
manufacturer’s protocol. The concentration of total RNAwas deter-
minedspectrophotometricallywithNanodrop® ND-1000 (National
Instruments Corporation, Texas, USA).
Total RNA of SH-SY5Y and FNC (100ng) was amplified with the
primer set for LH subunit [28] using the SuperScriptTM One-Step
RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s instructions.
1–2g of total RNA was reverse transcribed into cDNA by
using TaqMan reverse transcription reagents with random exam-
ers (Applied Biosystems Inc., Foster City, CA, USA). The profile of the
reverse transcription reaction was 10min at 25 ◦C, 30min at 48 ◦C,
and 5min at 95 ◦C. Each reverse transcription was carried out in
triplicate.
Expression of mRNA of Seladin-1/DHCR24, StAR, P450scc and
LHwas determined by quantitative RT-PCR. The relative amounts
of the mRNAs of the target genes were determined by calculating
the ratio between thesemRNAs and themRNAof the housekeeping
gene glyceraldehyde-3-phosphatedehydrogenase (GAPDH). In our
experimental systems, GnRH treatment did not change the expres-
sion of GAPDH. We observed comparable results using another
housekeepinggene,HPRT1, tonormalize the target geneexpression
(data not shown).
The quantification of Seladin-1/DHCR24 mRNA was performed
by real-time RT-PCR. TaqMan primers, probe and thermal cycling
conditions were as previously described [29]. PCR mixture (25l
final volume) included1×final concentrationofUniversal PCRMas-
ter Mix (Applied Biosystems), and 50ng of cDNA.
For the quantification of P450scc gene expression, 50ngof cDNA
were amplified in a reaction mixture (25l final volume) contain-
ing Power SYBR Green Master Mix (Applied Biosystems) at 1× final
concentration and the primer pair [30] at 0.5M concentration.
The cDNA was then subjected to PCR using the following condi-
tions: 10min at 95 ◦C, followed by 40 cycles at 95 ◦C for 15 s and
62 ◦C for 1min in the ABI Prism 7900 Sequence Detector (Applied
Biosystems).
Primer for StAR (Hs STAR 1 SG QuantiTect Primer Assay n.
QT00091959), LH (Hs LHB 1 SG QuantiTect Primer Assay n.
QT00207858) and GAPDH (Hs GAPDH 2 SG QuantiTect Primer
Assay n. QT01192646) were purchased from Qiagen. PCR mixture
(25l final volume) included 1× final concentration of QuantiTect
Primer assaymix, 1×final concentration of Power SYBRGreenMas-
ter Mix (Applied Biosystems) and 50ng cDNA. The thermal cycling
condition was 10min at 95 ◦C, followed by 40 cycles at 95 ◦C for
15 s and 60 ◦C for 1min in the ABI Prism 7900 Sequence Detector
(Applied Biosystems).
According to the comparative threshold cycle (Ct) method,
the amount of target mRNA normalized to GAPDH and rela-
tive to an internal control was calculated by 2−Ct. The results
(mean± SE) were expressed as fold mRNA variations compared
with control. Each sample of the RT triplicate, of any experimen-
Author's personal copy
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tal point, was measured in duplicate and 3–5 experiments were
performed.
2.4. Western blotting analysis for StAR
For Western blot analysis of SH-SY5Y, cell pellets from one 10-
cm culture plate were lysed in 200l RIPA buffer (150mM NaCl,
50mMTRISpH7.5, 1% (v/v)NonidetP-40, 0.5% (w/v) sodiumdeoxy-
cholate, 0.1% (v/v) SDS) with Protease inhibitor cocktail (Sigma),
vortexed and centrifuged at 13,000× g for 10min at 4 ◦C. Super-
natants from pellet extractions were analyzed for total protein
content using the BCA protein determination kit (Pierce, Rock-
ford, IL, USA). Twenty micrograms of total protein was loaded
for each sample, resolved by 10% SDS polyacrylamide gel elec-
trophoresis at 100V and transferred to polyvinylidene difluoride
(PVDF) membrane from Millipore (Billerica, MA, USA). The mem-
brane was blocked in blocking buffer (TBS-Tween20 0.1% (v/v), 5%
(w/v) skim milk) for 1h and incubated for 2h at room temperature
with anti-StAR antibody (Abcam, Cambridge, UK) diluted 1:3000 in
blocking buffer. After washing the membrane was incubated with
horseradish peroxidase-conjugated secondary antibody for 1h at
room temperature and revealed using the Immobilion Western
Chemiluminescent HRP Substrate (Millipore). The intensities of the
immunoreactive bands were quantified by Quantity One software
onaChemiDocXRS instrument (Bio-RadLaboratories,Hercules, CA,
USA). The StAR protein signals were corrected by F-actin signal.
2.5. Cholesterol measurement
Cells were plated at a density of 2×105 cells in six-wells plates,
maintained in serum free medium 24h and than treated with var-
ious concentrations of GnRH for the indicated periods.
The amount of cholesterol was determined by gas chro-
matography/mass spectrometry (GC/MS) as previously described
with minor modifications [31]. Briefly, cells from six wells plate
were harvested and lysed in NaOH 1N (200–300l/well) using
a cell scraper and frozen at −20 ◦C. The protein concentration
was determined by using the Bradford method [32]. 5–10g
of proteins was used for cholesterol determination. After the
addition of stigmasterol (1000ng) as internal standard, sterols
were extracted with n-hexane. After evaporation, sterols were
derivatized in bis-N,O-(trimethylsilyl)-trifluoroacetamide (BSTFA)
with 10% trimethyl-chlorosilane at 70 ◦C for 30min. BSTFA
solutions (2l) were automatically injected for analysis in a
Hewlett-Packard GC–MS system composed of a 6890 series II gas-
chromatographequippedwith a5973Mass SpectrometryDetector,
a 6890 automatic injector and a GC column was a J&W DB1
(15m×0.25mm×0.25m). A six point calibration curve in the
25–1000ng cholesterol range with 1000ng of stigmasterol was
used for cholesterol quantification. The peak area ratios (PAR)were
calculated using the signals at 458m/z and 484m/z for cholesterol
and stigmasterol, respectively.
The results (mean± SE) were expressed as fold cholesterol vari-
ations compared with control. All measurements were carried out
in triplicate and three experiments were performed.
Inter-assay CV% was less than 10% in all the concentration range
of the calibration curve.
2.6. E2 measurement
After incubation of SH-SY5Y with 1nM GnRH for 24, 48 and
72h the medium was harvested and its E2 content was determined
with an immunoassayusing the E2kit for IMMULITE2000 (Siemens
Healthcare diagnostics, Deerfield IL, USA) after an extraction step.
Briefly, for each point 750l of medium was extracted with 1ml of
terbutilmethyl ether (TBME) for two times. The TBME extract was
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Fig. 1. Seladin-1/DHCR24 expression after GnRH stimulus. Seladin-1/DHCR24
mRNA in SH-SY5Y cells (A) and in FNC cells (B) stimulatedwith 1.0nMGnRH. Values
are normalized using GAPDH as housekeeping gene and reported as x-fold variation
vs control. Each sample represents the mean± SE of the RT triplicate measured in
duplicate (6 measures in total). Five experiments were performed.
driedunder anitrogenflux, sampleswere reconstitutedwith250l
of the specific diluent and used for E2 quantification according to
the manufacturer’s instructions.
The sensitivity of the method was 15pg/ml and, assessed by
inter assay CV%, ranged from 7% at 1800pg/ml to 16% at 89pg/ml.
2.7. Statistical analysis
All data are expressed as mean± standard error (SE). Compar-
isons between the different groups were performed by ANOVA
followed by Bonferroni’s t-test. A P-value less than 0.05 was
accepted as statistically significant.
3. Results
3.1. GnRH modulates the expression of seladin-1/DHCR24 in
SH-SY5Y and FNC cells
To assess the role of GnRH in the modulation of cholesterol
biosynthesis SH-SY5Y cells were stimulated with GnRH at doses
from 0.01 to 1000nM and the seladin-1/DHCR24 mRNA was quan-
titatively determined by real time RT-PCR after the following
incubation times: 90min and 3, 6, 24, 48 and 72h. GnRH was
able to modulate seladin-1/DHCR24 expression only in a narrow
range between 0.2 and 2.0nM and the 1.0nM dose was selected for
Author's personal copy
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Fig. 2. StAR and P450scc expression after GnRH stimulus. StAR mRNA levels (A)
and western blotting analysis for StAR protein (B) in SH-SY5Y cells stimulated with
1.0nM GnRH. P450scc mRNA levels (C) in SH-SY5Y cells stimulated with 1.0nM
GnRH. For both target genes, values are normalized using GAPDH as housekeeping
gene and reported as x-fold variation vs control. Values for each sample represent
the mean± SE of the RT triplicate measured in duplicate (6 measures in total). Three
experiments were performed.
most of the studies. Seladin-1/DHCR24expressionwas significantly
up-regulated after 90min of incubation, down-regulated after 6h,
then it was again up-regulated after 24h and returned to its basal
value at 48 and 72h (Fig. 1A). Similar results were obtained with
FNC, in particular also in these cells only 1.0nM GnRH was able
to modulate seladin-1/DHCR24 expression, that was up-regulated
after 90min but resulted unchanged at the other incubation times
(Fig. 1B).
3.2. GnRH modulates the expression of StAR and P450scc
The same GnRH doses and incubation times were used to ver-
ify if GnRH was able to promote steroidogenesis by modulating
the expression of the genes codifying for StAR and P450scc. StAR
protein is responsible for cholesterol transport into the inner mito-
chondrial membrane and this represents the rate limiting step of
steroidogenesis. Cholesterol is then converted into the first steroid,
Fig. 3. LH expression after GnRH stimulus. A: LH mRNA in SH-SY5Y cells stimu-
lated with 1.0nM GnRH. Values are normalized using GAPDH as housekeeping gene
and reported as x-fold variation vs control. Values for each sample represent the
mean± SE of the RT triplicate measured in duplicate (6 measures in total). Three
experiments were performed. B: PCR amplification of LH subunit in untreated
SH-SY5Y cells. The size of the PCR product is 320-bp.
pregnenolone, by P450scc [33]. Similarly to what reported for
seladin-1/DHCR24, GnRH was active in the same narrow range
around 1.0nM in SH-SY5Y. A significant up-regulation of StAR
mRNA expression was observed after 90min and 3h of incuba-
tion, values returned to the basal levels after 6h and then remained
unchanged (Fig. 2A).Moreover, protein expressionof StARwas con-
firmed by western blot analysis. Results showed a strong increase
of 37kDa and 30kDa forms of StAR protein after 90min and 3h of
incubation with 1.0nM GnRH (Fig. 2B).
In addition, in these cells we registered a significant, up-
regulation of the expression of P450scc after 3 and 6h of treatment
with 1.0nM GnRH that subsequently come back to the basal lev-
els (Fig. 2C). In FNC GnRH was unable to modulate StAR protein
and P450scc expression at any concentration tested from 0.01 to
1000nM (not shown).
3.3. GnRH activity is mediated by LH
GnRH induces the expression of LH subunit in human neu-
roblastoma cells M17 [17]. We examined whether the same
phenomenon occurs in SH-SY5Y cells. We used these cells because,
differently from FNC, they were able to respond to GnRH through
the modulation of the expression of steroidogenesis related genes.
GnRH 1nM was able to up-regulate the expression of the LH sub-
unit after 90min of incubation in SH-SY5Y (Fig. 3A). LH is composed
Author's personal copy
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Fig. 4. Seladin-1/DHCR24, StAR and P450scc expression after GnRH stimulus and
LH-Receptor blockage. Seladin-1/DHCR24 mRNA (A), StAR mRNA (B) and P450scc
mRNA (C) in SH-SY5Y cells stimulated with 1.0nM GnRH after the blockage of LH-
ReceptorwithAb-LHR (1:200). Values arenormalizedusingGAPDHashousekeeping
gene and reported as x-fold variation vs control. Values for each sample represent
the mean± SE of the RT triplicate measured in duplicate (6 measures in total). Three
experiments were performed.
by two subunits. We verified by PCR if these cells constitutively
express the LH subunit (Fig. 3B).
To assess whether the effect of GnRH is mediated by LH, we
incubated SH-SY5Y cells with 1.0nM GnRH in the presence of
an antibody directed towards an extracellular domain of the LH-
receptor. mRNA levels of seladin-1/DHCR24, StAR and P450scc
were quantified by quantitative RT-PCR after 90min, 3 and 6h
of incubation. The LH-receptor blockage operated by the anti-
body completely reverted the up-regulation pattern observed with
1.0nM GnRH for all the three genes considered so demonstrating
the involvement of the LH signal in this phenomenon (Fig. 4A–C).
To definitely demonstrate this pointwe successively incubated SH-
SY5Y cells with LH 100mIU/ml finding a modulation pattern of
Fig. 5. Cell Cholesterol and E2 production after GnRH stimulus. A: Total cell choles-
terol in SH-SY5Y cells stimulated with 1.0nM GnRH. Values are reported as fold
variation vs control. The absolute amount of cholesterol measured for the control is
19.51±0.62ng cholesterol/g protein. Each point is performed in triplicate and the
results represent the mean± SE of five experiments. B: E2 amount released in the
medium of SH-SY5Y cells stimulated with 1.0nM GnRH. The absolute amount of E2
measured for the control is 1.75±0.19pg/ml. Values are reported as fold variation
vs control. Each point is performed in quadruplicate and the results represent the
mean± SE of two experiments.
the three genes similar to that induced by 1.0nM GnRH (data not
shown).
3.4. GnRH modulates cell cholesterol and E2 synthesis in SH-SY5Y
cells
To verify whether the modulation of the expression of seladin-
1/DHCR24 operated by 1.0nM GnRH induces a variation of cell
cholesterol we quantified this sterol by GC/MS in total cell lysates
after incubating SH-SY5Y for 90min, 3, 6, 24, 48 and 72h. The
results demonstrate a strong increment of cell cholesterol after
90min, values remain up-regulated at 3 and 6h, significantly
decrease after 24h to definitively return to the basal level after 48h
(Fig. 5A). These variations can be linked to the modulation of the
expression of seladin-1/DHCR24 supposing that the up-regulation
of this enzyme after 90min induces a rapid increment of choles-
terol synthesis. The decrement of cell cholesterol after 24h, that
could be due to its consumption during the steroidogenic process,
provokesanewup-regulationof seladin-1/DHCR24expression that
restores basal cholesterol levels. Cholesterol levels were not signif-
icantly increased after 1.0nM GnRH treatment in FNC cells (data
not shown).
Recently it was described that GnRH stimulates E2 synthesis in
rat primary hippocampal cultures. To assess whether GnRH expo-
sure causes E2 production in our human cell model we quantified
the amount of E2 released in the culture medium after incubation
Author's personal copy
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Fig. 6. Effect of GnRH on steroidogenesis in SH-SY5Y cells. Summary of the modulation of seladin-1/DHCR24, StAR, P450scc and LH expression, cell cholesterol amount and
E2 production after treatment of SH-SY5Y cells with 1.0nM GnRH. For each target the variation is represented by a smoothed curve connecting the experimental points.
with 1.0nM GnRH. E2 concentration results significantly increased
after 24, 48 and 72h of incubation indicating that 1.0nM GnRH
induces a steroidogenic impulse directed to the synthesis of E2
(Fig. 5B).
Fig. 6 summarizes the modulation of all the targets analyzed in
SH-SY5Y cells after treatmentwith 1nMGnRHeach represented by
a smoothed curve connecting the experimental points. This figure
well represents the global neurosteroidogenic process triggered by
GnRH. This process starts with a rapid rise of LH subunit, Seladin-
1/DHCR24 and cell cholesterol, followed by an up-regulation of
P450scc and a contemporary consumption of cholesterol to form
successively E2 as the end product.
4. Discussion
These results demonstrate, for the first time in a human neu-
ronal cell model, that GnRH stimulates steroidogenesis enhancing
both cholesterol and estrogen biosynthesis. GnRH is active only
at in a narrow range around 1nM while lower or higher concen-
trations are unable to stimulate steroidogenesis. The first GnRH
effect is registered after 90min with the up-regulation of LH
mRNA. At this incubation timewe observed the increase of seladin-
1/DHCR24 expression, cell cholesterol amount and StAR protein.
This is followed by the up-regulation of P450scc expression after
3h. The antibody used to block the LH-receptor completely reverts
the GnRH effect strongly suggesting that, similar to the HPG axis,
GnRH action is mediated by LH. The data obtained stimulating cells
directly with LH further support this hypothesis. The final event
of GnRH action is the enhancement of E2 synthesis that is regis-
tered after 24, 48, and 72h. Our results are in agreement with data
obtained by Prange-Kiel et al. [19] on rat hippocampal slices and
primary cells treated with GnRH. In fact also in these rat samples
GnRH acts with a bell shaped dose response curve and the final
steroid synthesized is estradiol. Our data addnew interesting infor-
mation demonstrating that GnRH action, in a human neuronal-like
cell model, is mediated by LH and modulates also the last step of
cholesterol biosynthesis, enhancing cell cholesterol.
Finally the studies presented here, although based on a neu-
roblastoma cell line, suggest a new physiological mechanism for
estrogen local synthesis in the brain through the action of GnRH
on GnRH responsive cells. This hormone could act as a com-
mon modulator of cholesterol and estrogen biosynthesis by an
autocrine-paracrine mechanism, strongly supporting the presence
of a local miniature endocrine axis. It remains to be seen whether
neurons responsive to GnRH in the CNS may respond similarly
in situ. Estrogens are fundamental neuro-steroids with a trophic
and protective role in the CNS [34,35] and the elucidation of this
regulatory mechanism for their local synthesis will add new infor-
mation on the CNS. In FNC cells, differently from SH-SY5Y cells,
1.0 nM GnRH does not represent a steroidogenic input. This point
can be explained considering that FNC cells are a long term pri-
mary culture of foetal neuroblast described as already committed
to become GnRH secreting neurons even if not completely dif-
ferentiated. The physiological role of GnRH secreting cells is to
respond to circulating levels of sex steroids and regulate GnRH
secretion for a correct functionality of the HPG axis. For this rea-
son an autocrine-paracrine production of E2 triggered by secreted
GnRH could represent an interference for their physiological role
and results inhibited. In agreementwith this hypothesis it has been
reported that the hypothalamus, that is under the control of circu-
lating steroids for the regulation of its neuroendocrine function,
shows a relatively low expression of StAR compared with other
brain areas. This reflects the low local steroid production in an area
whose function is dependent on systemic hormonal steroids [36].
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